NSCLC

This study tests whether giving two drugs (SHR-A1811 and adebelimumab) before surgery can shrink or eliminate HER2-altered non-small cell lung cancer. About 40 adults with early-stage, resectable cancer will receive the combination, then have surgery to remove any remaining tumor…

This study tests whether adding an allergy medicine (diphenhydramine) to standard chemo and immunotherapy (toripalimab) helps shrink lung cancer before surgery and prevent it from coming back after. About 120 people with stage IIA-IIIB non-small cell lung cancer will be randomly …

This study tests a new approach for people with early-stage non-small-cell lung cancer that can be removed with surgery. Before surgery, participants will receive a short course of targeted radiation (SBRT) combined with an immunotherapy drug (QL1706) and chemotherapy. The goal i…

This study tests whether adding the targeted drug bozitinib to standard chemotherapy can shrink tumors more effectively before surgery in people with a specific genetic subtype of lung cancer (MET-altered). About 34 adults with stage IIA to IIIC non-small cell lung cancer will re…

This study is for people with early-stage lung cancer who are already scheduled for a bronchoscopy (a scope procedure to take tissue samples). During that same procedure, doctors will use a special device that first freezes and then heats the tumor. The tumor will then be surgica…

This study tests a drug called Vebreltinib given for 8 weeks before surgery in people with a specific type of lung cancer (stage IIA-IIIB NSCLC with a MET gene change). The goal is to see if the drug can shrink tumors enough to improve surgery outcomes. About 30 participants will…

This study tests a new approach for people with operable non-small cell lung cancer that does not have certain gene changes. Instead of chemotherapy, participants will receive a short course of focused radiation (SBRT) plus two drugs: an immunotherapy (tislelizumab) and an antian…

This study looks at how safe and effective the drug SHR-A1811 is for Chinese patients with advanced or spreading non-small cell lung cancer that has a specific genetic change (HER2 alteration). Researchers will follow 1,000 people already receiving the drug in regular medical car…

This early-stage trial tests a new drug called TB511, alone or with pembrolizumab, in people with advanced solid tumors (lung, prostate, colorectal, or liver cancer) that stopped responding to standard treatments. The study has two parts: first, finding the safest dose of TB511 a…

This study tests whether adding a new drug (SYS6010) to the standard treatment osimertinib can help people with a certain type of advanced lung cancer (EGFR-mutant NSCLC) live longer without their cancer getting worse. About 680 adults aged 18 to 75 will be randomly assigned to r…

This study tests a new two-drug combination for people with advanced non-small cell lung cancer whose disease got worse after standard immunotherapy and chemotherapy. The drugs—gemcitabine (a chemotherapy) and ivonescimab (a targeted therapy)—are given together to try to shrink t…

This study tests a new drug called GFH276 in people with advanced cancers that have RAS mutations, including pancreatic, lung, and colorectal cancers. The goal is to see if the drug is safe and can shrink tumors or slow disease. About 450 adults aged 18-75 will take part in two p…

This study tests whether a new immunotherapy drug (iparomlimab and tuvonralimab) combined with targeted radiation (SBRT) can help control early-stage non-small cell lung cancer. About 28 adults with stage I-IIB disease will receive the treatment. The goal is to see if the combina…

This study tests a new drug called limertinib combined with radiation therapy as a first treatment for people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer) that has spread to the brain. The goal is to see if the combination can better control brain …

This study tests a new drug called rilapentib alpha combined with chemotherapy for people with stage II or III non-small cell lung cancer that can be removed with surgery. Participants receive the drug combo before surgery to shrink the tumor, then continue the new drug alone for…

This study tests a daily pill called iruplinalkib for people with early-stage (stage IA) ALK-positive non-small cell lung cancer who have high-risk factors. After surgery to remove the tumor, participants take the pill for up to three years to see if it helps keep the cancer from…

This pilot study will test whether a personalized exercise program is practical for 20 adults with stage II or III non-small cell lung cancer who have not yet started treatment. Participants will follow the Precise Exercise Regimen for Cancer Care (PERCC) program before beginning…

This study tests whether four weekly counseling sessions before lung cancer surgery can lower anxiety and depression. About 138 adults awaiting lung cancer surgery will be split into three groups: those who get the counseling, those who refuse it, and healthy volunteers. Research…

This early study tests a non-invasive device that sends low-intensity electric fields to lung tumors before surgery. The goal is to see how these fields affect certain genes in the cancer. 18 people with stage I-IIIA non-small cell lung cancer will take part. The main focus is sa…

This study looks at 300 lung cancer patients who had immunotherapy before surgery but still had some cancer left after the operation. Researchers will use advanced gene testing to find hidden genetic changes that might explain why the treatment didn't work completely. The goal is…